Cyclin Dependent Kinase Inhibitor Pipeline Insight
DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cyclin-Dependent Kinase Inhibitor Understanding
Cyclin-Dependent Kinase Inhibitor: Overview
Cyclin-dependent kinases (CDKs) are a family of enzymes-serine threonine kinases - that, under normal physiological conditions, play significant roles in controlling cell-cycle progression and transcription regulation. Overexpression of some CDKs and their associated cyclins, as well as downregulation of CDK inhibitors (CKIs), can lead to abnormal cellular proliferation and cancer progression. Due to such dysregulation of CDKs in many cancers, targeting of this family of enzymes has emerged as a promising strategy in the treatment of multiple cancer types, including blood and solid tumours. Targeting the cell cycle via the CDK4/6-Rb axis has proven the most successful approach in the clinic to date. The FDA has approved the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib as treatments for hormone receptor-positive (HR+) metastatic breast cancer (mBC), in combination with endocrine therapy.
"Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cyclin-Dependent Kinase Inhibitor pipeline landscape is provided which includes the disease overview and Cyclin-Dependent Kinase Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Cyclin-Dependent Kinase Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cyclin-Dependent Kinase Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Cyclin-Dependent Kinase Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Cyclin-Dependent Kinase Inhibitor.
Cyclin-Dependent Kinase Inhibitor Emerging Drugs Chapters
This segment of the Cyclin-Dependent Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cyclin-Dependent Kinase Inhibitor Emerging Drugs
SHR6390: Jiangsu Hengrui Medicine Co.
SHR-6390 acts as inhibitors of Cyclin-dependent kinase 4 and Cyclin-dependent kinase 6. It is being developed by Jiangsu Hengrui Medicine for the treatment of Breast cancer.
GB491 (lerociclib): Genor Pharma
GB491 (lerociclib) is a potent, selective, potentially best-in-class oral CDK4/6 for HR+/HER2-breast cancer in China. GB491 has consistently demonstrated efficacy in several pre-clinical models and clinical trials in HR+/HER2-breast cancer. CDK4/6 inhibitors in combination with fulvestrant represent an established treatment for HR+/HER2- advanced or metastatic breast cancer and have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS). Preliminary results of clinical trials indicate that GB491 has a differentiated PK and tolerability profile from other CDK4/6 inhibitors, allowing for continuous dosing with fewer dose-limiting toxicities such as neutropenia and less complete blood count monitoring. Lerociclib is currently undergoing a Phase IIa clinical trial conducted by licensing partner, G1 Therapeutics.
Further product details are provided in the report……..
Cyclin-Dependent Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Cyclin-Dependent Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cyclin-Dependent Kinase Inhibitor
There are approx. 40+ key companies which are developing the therapies for Cyclin-Dependent Kinase Inhibitor. The companies which have their Cyclin-Dependent Kinase Inhibitor drug candidates in the most advanced stage, i.e. Pre-registration include, Jiangsu Hengrui Medicine Co.
DelveInsight’s report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Cyclin-Dependent Kinase Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cyclin-Dependent Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclin-Dependent Kinase Inhibitor drugs.
Cyclin-Dependent Kinase Inhibitor Report Insights
- Cyclin-Dependent Kinase Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cyclin-Dependent Kinase Inhibitor Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cyclin-Dependent Kinase Inhibitor drugs?
- How many Cyclin-Dependent Kinase Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclin-Dependent Kinase Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cyclin-Dependent Kinase Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cyclin-Dependent Kinase Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?